Cure8 regulatory brief
This project seeks new biology-based treatments for IBD by finding bacterial enzymes that block PAR signaling, a pathway linked to inflammation, barrier loss, and pain — symptoms many people with Crohn’s disease or ulcerative colitis experience.
Researchers studying the gut microbiome, immune signaling, and drug discovery; clinicians interested in emerging IBD therapies; patients curious about microbiome-based therapeutic strategies.
NIH-funded Stanford project aims to identify and test proteases produced by gut commensal bacteria that can deactivate human protease-activated receptors (PARs).
The investigators will express and characterize bacterial proteases, then test whether these enzymes protect mice from barrier disruption, inflammation, nociceptor activation, and pain linked to IBD.
This is a funded research project (project record) describing planned laboratory and animal work to discover candidate bacterial-derived proteases as potential therapeutic agents; it is not a clinical trial reporting patient results.
The summary focuses on the scientific rationale (excessive proteolysis and dysregulated PAR signaling in IBD) and the experimental goals (identify, characterize, and demonstrate protective effects in mice).
If promising, this line of work could point toward new biology-based therapeutic approaches that modulate host receptors via microbially derived enzymes, but translation to human treatments would require additional preclinical safety, dosing, and clinical testing.
Project-record summary describes planned laboratory and murine studies funded by NIH; it does not report human clinical results. Findings in mice or in vitro do not guarantee safety or effectiveness in people and would need further preclinical and clinical development.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: National Institute of Diabetes and Digestive and Kidney Diseases - R01DK147117 - $3,802,100
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If successful, this approach could lower costs and simplify storage/transport of an established IBD antibody (adalimumab) and enable oral delivery, which would be relevant to people with Crohn’s disease or ulcerative...
The study suggests vitamin D might help the immune system tolerate gut bacteria better and lower intestinal inflammation, which could mean fewer symptoms or flares for people with Crohn’s disease or ulcerative colitis.
The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.
